DIHYDROERGOTAMINE MESYLATE

Post-LOE

dihydroergotamine mesylate

Sagent Pharmaceuticals

ANDAINJECTIONINJECTABLE

Approved

Jul 2018

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

4/8 — Partial

DIHYDROERGOTAMINE MESYLATE (dihydroergotamine mesylate) by Sagent Pharmaceuticals is clinical pharmacology mechanism of action dihydroergotamine binds with high affinity to 5-ht 1dα and 5-ht 1dβ receptors. Approved for migraine. First approved in 2018.

Drug data last refreshed 18h ago

Mechanism of Action

CLINICAL PHARMACOLOGY Mechanism of Action Dihydroergotamine binds with high affinity to 5-HT 1Dα and 5-HT 1Dβ receptors. It also binds with high affinity to serotonin 5-HT 1A, 5-HT 2A, and 5-HT 2C receptors, noradrenaline α 2A, α 2B and α 1 receptors, and dopamine D 2L and D 3 receptors. The…

Worked on DIHYDROERGOTAMINE MESYLATE at Sagent Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

DIHYDROERGOTAMINE MESYLATE

Mechanism of Action

Indications (1)

Clinical Trials (1)